ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Rhode Island » Cardiovascular Disease

Top Cardiovascular Disease Prescribers in Rhode Island

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
JOSEPH MAZZA MD

Cardiovascular Disease

14,438

$501K

993
866 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

16%
prescriptions for brand name drugs

Avg: 22%

$35
Average prescription price

Avg: $45

IRVING GILSON M.D.

Cardiovascular Disease

11,832

$489K

501
457 are 65+

3%
patients receiving schedule two controlled substances

Avg: 0%

11%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

17%
prescriptions for brand name drugs

Avg: 22%

$41
Average prescription price

Avg: $45

HOWARD HARONIAN MD

Cardiovascular Disease

11,224

$496K

735
675 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 22%

$44
Average prescription price

Avg: $45

THOMAS NOONAN MD

Cardiovascular Disease

10,902

$531K

617
559 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 22%

$49
Average prescription price

Avg: $45

CHRISTOPHER LUTTMANN MD

Cardiovascular Disease

10,864

$591K

605
554 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 22%

$54
Average prescription price

Avg: $45

SUHDONG HAHN MD

Cardiovascular Disease

10,681

$479K

313
289 are 65+

9%
patients receiving schedule two controlled substances

Avg: 0%

10%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

21%
prescriptions for brand name drugs

Avg: 22%

$45
Average prescription price

Avg: $45

WILLIAM LEVIN MD

Cardiovascular Disease

9,105

$312K

722
666 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

19%
prescriptions for brand name drugs

Avg: 22%

$34
Average prescription price

Avg: $45

NED HENRY GUTMAN M.D.

Cardiovascular Disease

8,693

$378K

570
524 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 22%

$44
Average prescription price

Avg: $45

KIRIT DESAI MD

Cardiovascular Disease

8,635

$367K

593
531 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

18%
prescriptions for brand name drugs

Avg: 22%

$42
Average prescription price

Avg: $45

GEORGE BOURGANOS MD

Cardiovascular Disease

8,566

$414K

656
595 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 22%

$48
Average prescription price

Avg: $45

HANI SABBOUR M.D.

Cardiovascular Disease

8,230

$629K

440
358 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 22%

$76
Average prescription price

Avg: $45

RICHARD IACOBUCCI MD

Cardiovascular Disease

7,998

$392K

289
263 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

9%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 22%

$49
Average prescription price

Avg: $45

SAJID SIDDIQ MD

Cardiovascular Disease

7,752

$253K

543
454 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

17%
prescriptions for brand name drugs

Avg: 22%

$33
Average prescription price

Avg: $45

FRANKLIN SCHNEIDER MD

Cardiovascular Disease

7,656

$366K

539
478 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 22%

$48
Average prescription price

Avg: $45

JACK KLIE MD

Cardiovascular Disease

6,986

$300K

266
242 are 65+

7%
patients receiving schedule two controlled substances

Avg: 0%

10%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 22%

$43
Average prescription price

Avg: $45

RICHARD SAN ANTONIO MD

Cardiovascular Disease

6,920

$314K

552
531 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 22%

$45
Average prescription price

Avg: $45

ROBERT CARNEVALE MD

Cardiovascular Disease

6,791

$253K

434
402 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

3%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 22%

$37
Average prescription price

Avg: $45

JON LAMBRECHT MD

Cardiovascular Disease

6,634

$289K

503
466 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 22%

$44
Average prescription price

Avg: $45

JOHN CAVA MD

Cardiovascular Disease

6,387

$400K

487
423 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

29%
prescriptions for brand name drugs

Avg: 22%

$63
Average prescription price

Avg: $45

CHRISTIAN HERARD MD

Cardiovascular Disease

6,354

$275K

169
143 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

9%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 22%

$43
Average prescription price

Avg: $45

STEPHEN KUTZ M.D., FACC

Cardiovascular Disease

6,267

$280K

443
409 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 22%

$45
Average prescription price

Avg: $45

DAVID BROZA MD

Cardiovascular Disease

6,209

$337K

457
418 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 22%

$54
Average prescription price

Avg: $45

STEVEN FERA MD

Cardiovascular Disease

6,140

$264K

456
434 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 22%

$43
Average prescription price

Avg: $45

KENNETH KORR MD

Cardiovascular Disease

5,998

$247K

419
387 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

19%
prescriptions for brand name drugs

Avg: 22%

$41
Average prescription price

Avg: $45

BRIAN ABBOTT MD

Cardiovascular Disease

5,977

$291K

392
357 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

27%
prescriptions for brand name drugs

Avg: 22%

$49
Average prescription price

Avg: $45

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank